We are live on ! Find out more
OMED

OncoMed Pharmaceuticals, Inc.
OMED

Delisted

OMED was delisted on the 22nd of April, 2019.

Back to rankings

53 hedge funds and large institutions have $66.3M invested in OncoMed Pharmaceuticals, Inc. in 2013 Q3 according to their latest regulatory filings, with 53 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
53
Holders Change
+53
Holders Change %
–
% of All Funds
1.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
53
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SAM
Sectoral Asset Management
Quebec, Canada
+$19.6M
2
BI
BVF Inc
California
+$7.26M
3
CII
CR Intrinsic Investors
Connecticut
+$5.01M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$4.98M
5
Primecap Management
Primecap Management
California
+$4.53M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
SAM
1
Sectoral Asset Management
Quebec, Canada
$16.2M +$19.6M +1,059,479 New
BI
2
BVF Inc
California
$6M +$7.26M +391,800 New
CII
3
CR Intrinsic Investors
Connecticut
$4.14M +$5.01M +270,592 New
Alyeska Investment Group
4
Alyeska Investment Group
Illinois
$4.12M +$4.98M +268,997 New
Primecap Management
5
Primecap Management
California
$3.75M +$4.53M +244,700 New
Franklin Resources
6
Franklin Resources
California
$3.35M +$4.05M +218,600 New
Fidelity Investments
7
Fidelity Investments
Massachusetts
$2.97M +$3.6M +194,100 New
BIT
8
BlackRock Institutional Trust
California
$2.5M +$3.02M +162,954 New
BFA
9
BlackRock Fund Advisors
California
$2.01M +$2.43M +131,168 New
TG
10
TCW Group
California
$1.91M +$2.32M +124,987 New
Deutsche Bank
11
Deutsche Bank
Germany
$1.78M +$2.16M +116,639 New
SCM
12
Sigma Capital Management
Connecticut
$1.53M +$1.85M +100,000 New
JP Morgan Chase
13
JP Morgan Chase
New York
$1.53M +$1.85M +99,775 New
WSA
14
Wall Street Associates
California
$1.49M +$1.81M +97,482 New
Vanguard Group
15
Vanguard Group
Pennsylvania
$1.49M +$1.8M +97,130 New
VAM
16
Visium Asset Management
New York
$1.16M +$1.4M +75,800 New
T. Rowe Price Associates
17
T. Rowe Price Associates
Maryland
$1.07M +$1.3M +69,900 New
PAMU
18
Pictet Asset Management (UK)
United Kingdom
$1.02M +$1.24M +66,900 New
MWNA
19
Marshall Wace North America
New York
$990K +$1.2M +64,649 New
D.E. Shaw & Co
20
D.E. Shaw & Co
New York
$731K +$884K +47,733 New
Millennium Management
21
Millennium Management
New York
$696K +$842K +45,466 New
SCA
22
SAC Capital Advisors
Connecticut
$595K +$721K +38,893 New
TC
23
TFS Capital
Pennsylvania
$508K +$614K +33,160 New
State Street
24
State Street
Massachusetts
$477K +$576K +31,100 New
GT
25
Glenmede Trust
Pennsylvania
$439K +$532K +28,700 New
1
2 3

OMED Hedge Fund Activity: Q3 2013 in Review

53 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q3 2013, worth a combined $66.3M.

Buyers outnumbered sellers: 53 funds opened new OMED positions and 0 closed out — a net gain of 53 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Sectoral Asset Management, opening a new position worth an estimated $19.6M.

  • 53 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q3 2013, up from 0 in Q2 2013.
  • Funds reported $66.3M of OncoMed Pharmaceuticals, Inc. stock for Q3 2013.
  • 53 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q3 2013 and 0 closed out, a net change of +53 holders.
  • The largest OncoMed Pharmaceuticals, Inc. buyer in Q3 2013 was Sectoral Asset Management, an estimated $19.6M added.

Based on aggregated 13F filings for Q3 2013.